Why is Krebs Biochem falling/rising?

As of 23-Sep, Krebs Biochemicals & Industries Ltd is experiencing a decline in its stock price, currently at 77.70, which reflects a decrease of 2.26 or 2.83%. The stock has underperformed its sector today by 2.48%, and its delivery volume has significantly dropped by 91.95% compared to the 5-day average, indicating falling investor participation. Over the past week, the stock has decreased by 0.97%, while it has shown a modest increase of 3.75% over the last month. However, the longer-term performance is concerning, with a year-to-date decline of 16.44% and a staggering 32.14% drop over the past three years. The company has reported negative results for the last three consecutive quarters, with a negative book value and a high debt-to-equity ratio, contributing to its weak long-term fundamental strength.
In the broader market context, the Sensex has seen a slight decline of 0.28% over the past week, which suggests that the market conditions are not overly unfavorable. However, Krebs Biochem's performance is notably worse than the benchmark, particularly in the long term, where it has underperformed significantly with a 32.14% drop over three years compared to the Sensex's gain of 45.26%. The company's weak financials, including negative EBITDA and declining net sales, further exacerbate its challenges, making it a risky investment compared to its historical valuations.